published meta-analysis   sensitivity analysis   studies

anti-interleukin-6 in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] COVACTA (Rosas), 2020 1.02 [0.62; 1.68] Declercq J (COV-AID), 2021 1.02 [0.39; 2.66] EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06] EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72] NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72] NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31] NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88] NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Rutgers, 2021 0.59 [0.33; 1.06] Talaschian, 2021 1.56 [0.34; 7.13] Veiga, 2021 2.70 [0.92; 7.92] 0.83[0.64; 1.06]CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, COVACTA (Rosas), 2020, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04577534 (COVIDSTORM), 0, Rosas (REMDACTA), 2021, Rutgers, 2021, Talaschian, 2021, Veiga, 20211412%2,504moderatelow death or transfer to ICUdetailed resultsBACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88] 0.97[0.50; 1.88]BACC Bay Tocilizumab Trial, 202010%242lownot evaluable deathsdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62] CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51] CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] COVACTA (Rosas), 2020 1.16 [0.73; 1.84] Declercq J (COV-AID), 2021 1.02 [0.39; 2.66] EMPACTA, 2020 1.13 [0.54; 2.40] EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06] EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72] Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12] Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50] NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72] NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31] NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88] NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18] RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37] RECOVERY, 2021 0.85 [0.76; 0.95] REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Rutgers, 2021 0.62 [0.36; 1.07] Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55] Talaschian, 2021 1.25 [0.30; 5.14] Veiga, 2021 2.70 [0.92; 7.92] 0.85[0.78; 0.93]BACC Bay Tocilizumab Trial, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COVACTA (Rosas), 2020, Declercq J (COV-AID), 2021, EMPACTA, 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04577534 (COVIDSTORM), 0, RCT-TCZ-COVID-19, 2021, RECOVERY, 2021, REMAP-CAP (tocilizumab), 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 2021230%8,939moderatelow deaths (time to event analysis only)detailed resultsCOVACTA (Rosas), 2020 1.16 [0.73; 1.84] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Rutgers, 2021 0.62 [0.36; 1.07] Talaschian, 2021 1.25 [0.30; 5.14] 0.93[0.71; 1.21]COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, Talaschian, 202146%1,486moderatenot evaluable clinical deteriorationdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09] CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12] CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20] EMPACTA, 2020 0.55 [0.33; 0.92] RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86] Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77] 0.79[0.60; 1.04]BACC Bay Tocilizumab Trial, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, EMPACTA, 2020, RCT-TCZ-COVID-19, 2021, Soin AS (COVINTOC), 202165%818moderatenot evaluable clinical improvementdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] Dongsheng Wang, 2020 2.37 [0.40; 13.96] EMPACTA, 2020 1.15 [0.90; 1.47] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15] 1.21[1.03; 1.43]BACC Bay Tocilizumab Trial, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, EMPACTA, 2020, Lescure (Sarilumab 200mg), 2021, REMAP-CAP (tocilizumab), 2021633%1,747moderatenot evaluable clinical improvement (28-day)detailed resultsCOVACTA (Rosas), 2020 1.19 [0.81; 1.75] 1.19[0.81; 1.75]COVACTA (Rosas), 202010%438moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsEMPACTA, 2020 1.15 [0.90; 1.47] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54] 1.11[0.95; 1.31]EMPACTA, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 202130%506moderatenot evaluable death or ventilationdetailed resultsBACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81] CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22] CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31] EMPACTA, 2020 0.56 [0.32; 0.97] RECOVERY, 2021 0.85 [0.78; 0.93] Rosas (REMDACTA), 2021 0.98 [0.72; 1.34] Rutgers, 2021 0.65 [0.43; 0.99] Veiga, 2021 1.54 [0.65; 3.63] 0.84[0.74; 0.96]BACC Bay Tocilizumab Trial, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, EMPACTA, 2020, RECOVERY, 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, Veiga, 2021811%5,203moderatenot evaluable hospital dischargedetailed resultsEMPACTA, 2020 1.16 [0.90; 1.49] Rosas (REMDACTA), 2021 0.97 [0.79; 1.20] 1.05[0.88; 1.25]EMPACTA, 2020, Rosas (REMDACTA), 2021213%649moderatenot evaluable mechanical ventilationdetailed resultsCOVACTA (Rosas), 2020 0.67 [0.39; 1.14] RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69] Rutgers, 2021 0.65 [0.35; 1.24] Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38] 0.76[0.54; 1.09]COVACTA (Rosas), 2020, RCT-TCZ-COVID-19, 2021, Rutgers, 2021, Soin AS (COVINTOC), 202140%932moderatenot evaluable ICU admissiondetailed resultsCOVACTA (Rosas), 2020 0.48 [0.25; 0.94] Rutgers, 2021 0.96 [0.55; 1.68] Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64] 0.85[0.49; 1.49]COVACTA (Rosas), 2020, Rutgers, 2021, Soin AS (COVINTOC), 2021357%724moderatenot evaluable recoverydetailed resultsTalaschian, 2021 0.64 [0.14; 2.92] 0.64[0.14; 2.92]Talaschian, 202110%36moderatenot evaluable serious adverse eventsdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53] COVACTA (Rosas), 2020 0.81 [0.54; 1.22] Dongsheng Wang, 2020 0.91 [0.02; 47.31] Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12] Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51] Rosas (REMDACTA), 2021 0.83 [0.59; 1.18] Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13] Talaschian, 2021 7.93 [0.37; 171.38] Veiga, 2021 1.66 [0.60; 4.59] 0.98[0.80; 1.20]BACC Bay Tocilizumab Trial, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 202190%2,234moderateserious adverse eventsdetailed resultsCOVACTA (Rosas), 2020 0.87 [0.52; 1.45] Dongsheng Wang, 2020 9.64 [2.76; 33.75] Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69] Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27] Rosas (REMDACTA), 2021 1.32 [0.92; 1.89] Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87] Veiga, 2021 1.65 [0.81; 3.37] 1.37[0.98; 1.93]COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Soin AS (COVINTOC), 2021, Veiga, 2021757%1,956moderatenot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2022-05-27 05:33 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 557,635,1236,553,628,646,645,607,395 - roots T: 290